Where is Summit Therapeutics (SMMT) Headed According to Analysts?

Core Viewpoint - Summit Therapeutics Inc. (NASDAQ:SMMT) is recognized as a biotech stock with high potential, but it faces mixed ratings from analysts, indicating uncertainty in its investment outlook [1][2][3]. Analyst Ratings - Leerink Partners maintained a Sell rating on Summit Therapeutics without a price target as of September 29 [1]. - Barclays also issued a Sell rating with a price target of $13 on September 25 [2]. - In contrast, Asthika Goonewardene from Truist Financial maintained a Buy rating without a price target on the same day [2]. - Citi's Yigal Nochomovitz expressed a bullish outlook, assigning a Buy rating with a price target of $35 on September 24 [3]. Company Overview - Summit Therapeutics is a biopharmaceutical company focused on developing novel medications for infectious and cancerous diseases [3].